positive outlook, ignore noise from Swamy
Forecast Data
2025Q4 Forecast:
EPS: $2.09 (vs. $5.98 in 2024Q4, -65% YoY)
Gross Income: $113.39B (vs. $101.27B in 2024Q4, +12% YoY)
EBIT: $3.28B (vs. $5.78B in 2024Q4, -43% YoY)
Key Metrics:
Net Profit Margin (2025Q3): 2.07% (down from 5.50% in 2024Q4)
Gross Margin (2025Q3): 18.24% (down from 21.14% in 2024Q4)
Relevant Opinion
Policy risks persist as the Senate’s failure to extend Affordable Care Act subsidies pressures healthcare peers like Centene and Molina 1. While UNH’s diversified revenue streams may cushion policy impacts, sentiment remains fragile.
Analysts highlight potential upside with a mean target price of $389.62 (19% above current $327.45), driven by expectations of post-shutdown economic normalization 1.
Options Bulk Order
Notable Trades:
Large put buys (e.g., 1,540 contracts of $360 put expiring Nov 14) suggest hedging against downside risk.
Significant put selling (e.g., 5,120 contracts of $400 put expiring Dec 5) implies confidence in near-term stability above $350.
Takeaway: Mixed signals reflect caution but no broad bearish consensus.
Recent Quote
Price Trend: Stock fell 5.17% pre-earnings (Sept 30–Nov 12) but rebounded 1.83% on Nov 12.
Technical Levels:
Support: $302.6 (tested during recent pullback).
Resistance: $346.6 (breach could signal momentum shift).
Sentiment: Weak Q3 margins (net profit -54% QoQ) weigh on sentiment, but valuation at 17.04 P/E (below 5-year average of 21) offers margin of safety.
Forecast Conclusion
UnitedHealth’s Q4 faces headwinds from margin compression and policy risks, but its diversified model and undemanding valuation provide downside protection. Analysts see upside if execution improves, though healthcare sector volatility warrants caution.
2025Q4 Forecast:
EPS: $2.09 (vs. $5.98 in 2024Q4, -65% YoY)
Gross Income: $113.39B (vs. $101.27B in 2024Q4, +12% YoY)
EBIT: $3.28B (vs. $5.78B in 2024Q4, -43% YoY)
Key Metrics:
Net Profit Margin (2025Q3): 2.07% (down from 5.50% in 2024Q4)
Gross Margin (2025Q3): 18.24% (down from 21.14% in 2024Q4)
Relevant Opinion
Policy risks persist as the Senate’s failure to extend Affordable Care Act subsidies pressures healthcare peers like Centene and Molina 1. While UNH’s diversified revenue streams may cushion policy impacts, sentiment remains fragile.
Analysts highlight potential upside with a mean target price of $389.62 (19% above current $327.45), driven by expectations of post-shutdown economic normalization 1.
Options Bulk Order
Notable Trades:
Large put buys (e.g., 1,540 contracts of $360 put expiring Nov 14) suggest hedging against downside risk.
Significant put selling (e.g., 5,120 contracts of $400 put expiring Dec 5) implies confidence in near-term stability above $350.
Takeaway: Mixed signals reflect caution but no broad bearish consensus.
Recent Quote
Price Trend: Stock fell 5.17% pre-earnings (Sept 30–Nov 12) but rebounded 1.83% on Nov 12.
Technical Levels:
Support: $302.6 (tested during recent pullback).
Resistance: $346.6 (breach could signal momentum shift).
Sentiment: Weak Q3 margins (net profit -54% QoQ) weigh on sentiment, but valuation at 17.04 P/E (below 5-year average of 21) offers margin of safety.
Forecast Conclusion
UnitedHealth’s Q4 faces headwinds from margin compression and policy risks, but its diversified model and undemanding valuation provide downside protection. Analysts see upside if execution improves, though healthcare sector volatility warrants caution.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
